מכפיל EV/EBITDA: vTv Therapeutics, Inc. (VTVT)

vTv Therapeutics Inc. (VTVT) generates revenue based on bringing metabolism therapies to market, including the drug TTP399 and developments targeting psoriasis. This chart on GURU.Markets confirms this, recording the metric at 0.00. An innovative glucose regulation method allows the company to maintain pricing power. However, the platform's success depends on the FDA's verdict, and patent protection has not yet created a sustainable cash flow.
vTv Therapeutics, Inc. (VTVT) - פילוחי מדדים ודוחות פיננסיים

EV/EBITDA assesses the business value relative to its operating profit before depreciation, taxes, and interest, allowing for the determination of the real value of assets without the influence of debt load. By analyzing the EV/EBITDA level over a time interval, an investor identifies the undervaluation of vTv Therapeutics Inc. (VTVT), given that the current market confidence is based on expectations regarding the update of clinical programs and the effectiveness of new management.